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N-glycolylneuraminic acid (Neu5Gc)-containing glycans are a prominent form of aberrant glycosylation
found in human tumor cells and have been proposed as cancer biomarkers. The B subunit of the subtilase
cytotoxin (SubB) produced by Shiga toxigenic Escherichia coli recognises Neu5Gc containing glycans. We
have previously engineered this lectin, SubB2M, for greater specificity and enhanced recognition of
Neu5Gc-containing glycans. Here we further explore the utility of SubB2M to detect Neu5Gc tumor
biomarkers in sera from patients with ovarian cancer. Using surface plasmon resonance (SPR) we show
that SubB2M can detect the established ovarian cancer biomarker, CA125, in a highly sensitive and
specific fashion in the context of human serum. These studies established conditions for screening serum
samples from patients with ovarian cancer for Neu5Gc glycans. We found that serum from patients with
all stages of ovarian cancer had significantly elevated mean levels of Neu5Gc glycans compared to normal
controls. Serum from patients with late stage disease (stages IIIC, IV) had uniformly elevated levels of
Neu5Gc glycans. Detection of Neu5Gc-glycans using SubB2M has the potential to be used as a diagnostic
ovarian cancer biomarker, as well as a tool for monitoring treatment and disease progression in late stage
disease.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Ovarian cancer has the highest rate of mortality among the
gynecologic malignancies [1]. The five-year survival rate is less than
20% in women diagnosed with late stage ovarian cancer but in-
creases to over 90% when detected in early stages (stage I-II).
However, patients are typically diagnosed in the late stages due to
the largely asymptomatic nature of this disease in the early stages
[2] and the lack of highly sensitive and specific biomarkers. The best
currently available biomarker for ovarian cancer is the human
cancer antigen 125 (CA125), also known as MUC16, a heavily gly-
cosylated mucin [3]. Serum CA125 levels are elevated in approxi-
mately 80% of ovarian cancer cases at the time of diagnosis [4].riffith University, Gold Coast
riffith University, Gold Coast
), m.jennings@griffith.edu.au
r Inc. This is an open access articleHowever, CA125 serum levels may also be elevated in nonmalig-
nant conditions such as endometriosis [5], pregnancy [6], ovarian
cysts [7], pelvic inflammatory disease [8], hepatitis [9], cirrhosis
[10] and in the follicular phase of the menstrual cycle [11]. Due to
the limitations of CA125 as a biomarker, it is currently only
approved by the FDA to be used to monitor the response to therapy
and disease recurrence [12].
Glycans terminating with N-glycolylneuraminic acid (Neu5Gc)
are not expressed at significant levels on healthy human tissues, as
humans express an inactive cytidine monophosphate N-ace-
tylneuraminic acid (Neu5Ac) hydroxylase (CMAH) enzyme [13,14].
However, Neu5Gc-containing glycans are found in human tumor
tissues and cells [15e19] and have been proposed as a tumor an-
tigen [18,20,21]. While there are analytical methods available
[22,23] and a commercially available IgY antibody [24] for the
detection of Neu5Gc, we improved upon this by developing a lectin
with enhanced sensitivity and specificity for this glycan in complex
biological samples. We engineered the B subunit of the Shiga
toxigenic Escherichia coli (STEC) Subtilase cytotoxin (SubAB) to
reduce the recognition of Neu5Ac and broaden the Neu5Gc linkageunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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SubB2M [25,26]. Here we describe the analysis of serum samples
from patients with ovarian cancer compared to normal, cancer-free
females using SubB2M via surface plasmon resonance (SPR).
2. Materials and methods
2.1. Expression and purification of SubB2M
The recombinant SubB2M proteinwas expressed and purified as
previously described [25,27]. Briefly, SubB2M was expressed in
E. coli BL21 (DE3) cells transformed with the SubB2M expression
construct as a His6-tagged fusion protein, which was purified by Ni-
NTA affinity chromatography.
2.2. SPR analysis of CA125 spiked into normal human serum and
detection of Neu5Gc glycans in human serum samples
SPR was conducted using the Biacore S200 system (GE) with
immobilisation of SubB2M performed as described previously [28].
SubB2M (capture level: 4974e5483 Response Units (RU)) and anti-
CA125 mAb X325 (Bio-Rad) (capture level: 6538e7531 RU) were
immobilized onto flow cell 2 and 3 of a series S sensor chip CM5
(GE) using the NHS capture kit and flow cell 1 was run as a blank
immobilisation. Human cancer antigen 125 (CA125) was purchased
fromMyBioSource (San Diego, USA) andwas purified from a human
ovarian carcinoma cell line and provided at a concentration of
84,040 units/ml. Human CA125 was spiked into 1% normal human
serum diluted in PBS (the zero CA125 concentration control). Hu-
man CA125 was serially diluted 1:2 from 75 units/ml to 0.1465
units/ml in 1% normal human serum with the range from 18.75 to
0.1465 units/ml (equivalent to 1875 units/ml e 14.65 units/ml in
100% serum) shown in Fig. 1. Normal female serum is reported to
contain <35 units/ml of CA125 [4,29] or similar levels (63.2, 39.8)
[28], while serum from patients with advanced stage ovarian can-
cer have been reported to contain 215.8e1977 CA125 units/ml [30],
a mean of 645 CA125 units/ml [31] and up to 8100 CA125 units/ml
[4]. SPR analysis was performed using multi-cycle analysis and
double reference (values from flow cell 1 and 1% normal human
serum only) subtraction using the Biacore S200 evaluation soft-
ware, as previously described [26].
SPR analysis of human serum samples was performed as
described above. The serum samples were diluted 1:100 in PBS and
analysed in duplicate individually. SPR analysis was performed
using multi-cycle analysis and double reference (values from flow
cell 1 and PBS buffer only) subtraction using the Biacore S200
evaluation software.Fig. 1. SPR analysis of SubB2M and anti-CA125 mAb X325 detecting human CA125
spiked into normal human serum. 1% normal human serum was spiked with a
concentration range of human CA125 (18.75e0.1465 CA125 units/ml) and detected
with SubB2M and the X325 mAb. 1% normal human serum served as the zero con-
centration control.2.3. Human serum samples
22 serum samples from normal human females, 12 serum
samples from patients with stage I ovarian cancer, 11 with stage II
ovarian cancer, 10 with stage IIIC ovarian cancer and 14 with stage
IV ovarian cancer were obtained from the Victorian Cancer Biobank
under application 17020. ‘Normal’ controls are defined as patients
with an apparent non-malignancy diagnosis at the time the sample
is taken. The patient data and serum samples used in this project
were provided by the Victorian Cancer Biobank with appropriate
ethical approval. The Victorian Cancer Biobank, through the Cancer
Council Victoria as Lead Agency, is supported by the Victorian
Government through the Victorian Cancer Agency, a business unit
of the Department of Health and Human Services. Information
regarding each of the serum samples used in this study is sum-
marized in Supplementary Table 1.2.4. Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.0.
The differences between normal serum samples compared to
cancer patient serum samples were analysed by two-tailed t-tests,
with a P value of <0.05 considered significant.3. Results
3.1. SubB2M can detect CA125 spiked into normal human serum
In our previous study we showed that SubB2M can detect
bovine glycoproteins, known to be decorated with Neu5Gc, when
spiked into normal human serum [26]. In the current study, we
investigated whether SubB2M could detect the human tumor an-
tigen CA125 when present in normal human serum. CA125 is
heavily glycosylated, with 249 potential N-glycosylation and over
3700 potential O-glycosylation sites [3,30,32]. It has been shown
that CA125 from the serum of patients with ovarian cancer has
increased levels of sialylated glycans compared to normal controls
[30], therefore we used CA125 in our SPR analysis as an example of
the type of Neu5Gc-containing tumor antigens that would be ex-
pected to be overexpressed in human ovarian cancer.
Purified CA125 from a human ovarian cancer cell linewas spiked
into normal human serum at concentrations found in normal fe-
male serum (<35 CA125 units/ml) [4] up to concentrations previ-
ously reported for serum from patients with advanced stage
ovarian cancer (215.8e1977 CA125 units/ml) [30]. These spiked
samples were prepared in 1% normal human serum, as our previous
study showed that this dilution of human serum gave the best
signal-to-noise ratio [26].
To verify that our method of detection using SubB2M was reli-
able, we also analysed the CA125-spiked serum samples with an
anti-CA125 monoclonal antibody, clone X325. This mAb recognises
epitope group B of CA125, similar to the M11 antibody.
SubB2M showed concentration dependent recognition of CA125
(Fig. 1) and was able to detect down to 0.1465 CA125 units/ml in 1%
serum. This is equivalent to a sensitivity of 14.65 CA125 units/ml in
100% serum. These data confirm that SubB2M can detect Neu5Gc-
containing human tumor antigens in the context of a complex
sample, such as human serum, in a concentration-dependent
fashion. The anti-CA125 antibody, X325, also showed
concentration-dependent detection of CA125 via SPR, verifying our
method for detection of this human tumor antigen. We note that
SubB2M had superior sensitivity in detecting CA125 (14.65 CA125
units/ml) compared to the anti-CA125mAb X325, which could only
detect down to 58.6 CA125 units/ml.
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in early and late stage ovarian cancer
We next assessed whether the SubB2M lectin could detect
elevated levels of Neu5Gc in serum samples from ovarian cancer
patients with both early and late stage cancer. We obtained a
collection of ovarian cancer serum samples, along with normal
female serum samples from a similar age range, from the Victorian
Cancer Biobank. ‘Normal’ controls are defined as patients with an
apparent non-malignancy diagnosis at the time the sample is
taken. The serum samples were collected immediately pre-
operatively and were processed and stored within 2 h of collec-
tion. Fig. 2A shows the analysis of 12 stage I, 11 stage II, 10 stage IIIC
and 14 stage IV ovarian cancer serum samples, as well as serum
from 22 normal females via SPR. We detected significantly elevated
levels of Neu5Gc in serum samples from ovarian cancer patients in
stage I, II, IIIC and IV compared to normal females, with consistently
high levels observed in stages IIIC and IV. Detailed information for
each of the serum samples can be found in Supplementary Table 1.3.3. Elevated Neu5Gc levels observed are not entirely due to
elevated CA125 levels
CA125 has been shown to be elevated in the serum of up to 80%Fig. 2. SPR analysis of SubB2M with normal and stage I e IV ovarian cancer serum
samples. A) Average response units from duplicates for each serum sample are shown.
Error bars¼± 1 SD from the mean for each group. Statistical analysis was performed
using two-tailed t-tests. **** ¼ P-value <0.0001. B) Table showing the number of serum
samples, age range and mean Neu5Gc levels in SPR RUs for each group. The values in
parenthesis equal minimum e maximum RU values for each group of samples deter-
mined by SPR.of patients with ovarian cancer [4], therefore we were interested to
know if the elevated levels of Neu5Gc being detected by SubB2M
were due to elevated levels of CA125. The CA125 levels in 14 of the
ovarian cancer serum samples were provided by the Victorian
Cancer Biobank and were determined within 7 days before or after
collection of the serum sample used in our study. There was no
correlation between levels of Neu5Gc and CA125 levels for these 14
samples, suggesting that there are other Neu5Gc-containing bio-
markers elevated in the serum of these ovarian cancer patients that
remain to be identified.
4. Discussion
Ovarian cancer has the highest mortality rate of the female
reproductive cancers, mainly due to late diagnosis resulting from
the lack of specific symptoms for this disease [1,2]. Methods for the
detection of ovarian cancer in the early stages would therefore
improve survival rates. Using our engineered Neu5Gc specific lec-
tin, SubB2M, we showed via SPR that Neu5Gc levels are signifi-
cantly elevated in serum samples from ovarian cancer patients at
stages I, II, IIIC and IV. The range of Neu5Gc levels obtained for the
normal serum samples was from 26.32 to 73.48 SPR response units
(RUs). Only 3 of the 12 samples with stage I ovarian cancer fell
within this range while 5 out of 11 of the stage II ovarian cancer
samples were within this range. These data indicate that Neu5Gc
levels are elevated in the majority of stage I/II ovarian cancer serum
samples analysed in this study and that Neu5Gc-containing tumor
antigens have the potential to serve as diagnostic markers for
detection of early stage ovarian cancer. None of the serum samples
from the stage IIIC and IV cancer patients fell within the normal
ranges for Neu5Gc levels demonstrating that Neu5Gc is uniformly
elevated in late stage ovarian cancer. Moreover, Neu5Gc levels in all
of the stage IIIC and IV samples exceeded the mean level plus 3
standard deviations for the age-matched normal sera, indicating
high specificity and sensitivity.
SPR is a highly sensitive, label-free, and rapid optical detection
method and is increasingly being improved for clinical applications
(see reference 33 for a recent review). However, the drawbacks of
current commercial SPR sensors for clinical settings include their
relatively large footprint and high cost [33]. Also, a range of di-
lutions of the serum samples had to be performed, with the data
presented in this study obtained from 1% dilutions. While dilution
of the serum samples is advantageous in that very little sample is
required from the patient for analysis, the dilution factor of serum
samples from some patientsmay need to be individually optimized.
We noticed that with some of the serum samples, at concentrations
above 1%, an over-saturation effect was occurring where the RUs
would plateau then decrease. The molecular weight of the Neu5Gc-
conjugates being detected by SubB2M via SPR may influence the
RUs detected, with larger molecular structures potentially causing a
greater refractive index shift resulting in higher RUs. For example,
we noticed that the patient with the lowest Neu5Gc value recorded
(specimen no. 08SH256) had elevated levels of CA19.9 (also known
as sialyl Lewis A). This individual may have elevated levels of free
Neu5Gc containing glycans, which may result in lower RUs
compared to a serum sample with elevated levels of high-
molecular weight Neu5Gc-containing glycoproteins or glycolipids.
Identifying and characterizing the Neu5Gc-containing glyco-
conjugates that are being detected by SubB2M and using these data
to improve current ovarian cancer diagnostic methods is currently
under investigation.
It has been reported that the origin of Neu5Gc in humans is
dietary incorporation of this non-human glycan from animal
sources, particularly redmeat [34], and it is established that ovarian
cancer cells secrete Neu5Gc glycoconjugates [15]. However, it has
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endogenous Neu5Gc [35]. Our data showing uniformly elevated
levels of Neu5Gc in the serum of ovarian cancer patients supports
the latter hypothesis.
The capacity to diagnose ovarian cancer in early stages will have
a significant impact on patient survival rates. Biomarkers that can
monitor response to treatment and disease progression are also
needed. SubB2M can detect Neu5Gc-glycans at early stages of
ovarian cancer and detects uniformly high levels in late stage dis-
ease. The detection of Neu5Gc-glycans using SubB2M has the po-
tential to be used as a diagnostic tool, and as a liquid biopsy for
monitoring treatment and disease progression. As a research re-
agent SubB2M has the potential to help identify novel Neu5Gc
biomarkers for ovarian cancer.
Note
Receiver operating characteristic (ROC) analysis of the data in
Figure 2 was performed and revealed the ability of Neu5Gc levels to
distinguish between two diagnostic groups (diseased/normal).
Area under the curve (AUC) values of 1.0¼ 100% accurate diagnostic
test: Normal vs Stage I: optimal cutoff ¼ >62.94RU (sensitivity ¼
91.67%, specificity ¼ 86.36%); AUC ¼ 0.9053), Normal vs Stage II:
optimal cutoff ¼ >61.02RU (sensitivity ¼ 90.91%, specificity ¼
81.82%); AUC ¼ 0.9298, Normal vs Stage III: optimal cutoff ¼
>162.9RU (sensitivity ¼ 100%, specificity ¼ 100%); AUC ¼ 1.00,
Normal vs Stage IV: optimal cutoff ¼ >162.7RU (sensitivity ¼ 100%,
specificity ¼ 100%); AUC ¼ 1.00.
Funding
This work was supported by National Health and Medical
Research Council (NHMRC) Program Grant 1071659 (to JCP and
MPJ), NHMRC Project Grant 1084050 (to AWP) and NHMRC Prin-
cipal Research Fellowship 1138466 (to MPJ).
Disclosure
The following authors (JCP, AWP, CJD and MPJ) declare that they
are named inventors on a patent on matter contained in this
manuscript.
Acknowledgements
We thank the Victorian Cancer Biobank for providing all patient
data and serum samples.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.bbrc.2018.11.001.
References
[1] United States Cancer Statistics Working Group, United States Cancer Statistics
(USCS): 1999-2014 Cancer Incidence and Mortality Data, 2017 from, https://
nccd.cdc.gov/uscs/. (Accessed 17 August 2018).
[2] American CancerSociety, Survival Rates for Ovarian Cancer, by Stage, 2016
from, https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-
staging/survival-rates.html. (Accessed 16 August 2018).
[3] B.W. Yin, K.O. Lloyd, Molecular cloning of the CA125 ovarian cancer antigen:
identification as a new mucin, MUC16, J. Biol. Chem. 276 (2001)
27371e27375.
[4] R.C. Bast Jr., T.L. Klug, E. St John, E. Jenison, J.M. Niloff, H. Lazarus,
R.S. Berkowitz, T. Leavitt, C.T. Griffiths, L. Parker, V.R. Zurawski Jr., R.C. Knapp,
A radioimmunoassay using a monoclonal antibody to monitor the course of
epithelial ovarian cancer, N. Engl. J. Med. 309 (1983) 883e887.
[5] L.C. Giudice, A.J. Jacobs, C.E. Bell, L. Lippmann, Serum levels of CA-125 inpatients with endometriosis, Gynecol. Oncol. 25 (1986) 256e258.
[6] Y. Haga, K. Sakamoto, H. Egami, R. Yoshimura, M. Akagi, Evaluation of serum
CA125 values in healthy individuals and pregnant women, Am. J. Med. Sci. 292
(1986) 25e29.
[7] D.E. Pittaway, J.A. Fayez, J.W. Douglas, Serum CA-125 in the evaluation of
benign adnexal cysts, Am. J. Obstet. Gynecol. 157 (1987) 1426e1428.
[8] H. Halila, U.H. Stenman, M. Seppala, Ovarian cancer antigen CA 125 levels in
pelvic inflammatory disease and pregnancy, Cancer 57 (1986) 1327e1329.
[9] A. Ruibal, R. Siurana, G. Encabo, A. Cuartero, [Serum CA 1,25 in patients with
non-ovarian tumors. Evidence of a relation between the increase of the an-
tigen and hepatic disease], Med. Clin. 84 (1985) 376e377.
[10] J.F. Bergmann, M. Beaugrand, H. Labadie, J.M. Bidart, C. Bohuon, CA 125
(ovarian tumour-associated antigen) in ascitic liver diseases, Clin. Chim. Acta
155 (1986) 163e165.
[11] T. Masahashi, K. Matsuzawa, M. Ohsawa, O. Narita, T. Asai, M. Ishihara, Serum
CA 125 levels in patients with endometriosis: changes in CA 125 levels during
menstruation, Obstet. Gynecol. 72 (1988) 328e331.
[12] P. Bottoni, R. Scatena, The role of CA 125 as tumor marker: biochemical and
clinical aspects, Adv. Exp. Med. Biol. 867 (2015) 229e244.
[13] N.M. Varki, A. Varki, Diversity in cell surface sialic acid presentations: impli-
cations for biology and disease, Lab. Invest. 87 (2007) 851e857.
[14] H.H. Chou, T. Hayakawa, S. Diaz, M. Krings, E. Indriati, M. Leakey, S. Paabo,
Y. Satta, N. Takahata, A. Varki, Inactivation of CMP-N-acetylneuraminic acid
hydroxylase occurred prior to brain expansion during human evolution, Proc.
Natl. Acad. Sci. U. S. A. 99 (2002) 11736e11741.
[15] S. Inoue, C. Sato, K. Kitajima, Extensive enrichment of N-glycolylneuraminic
acid in extracellular sialoglycoproteins abundantly synthesized and secreted
by human cancer cells, Glycobiology 20 (2010) 752e762.
[16] A.N. Samraj, H. Laubli, N. Varki, A. Varki, Involvement of a non-human sialic
acid in human cancer, Front Oncol 4 (2014) 33.
[17] H. Higashi, Y. Hirabayashi, Y. Fukui, M. Naiki, M. Matsumoto, S. Ueda, S. Kato,
Characterization of N-glycolylneuraminic acid-containing gangliosides as
tumor-associated Hanganutziu-Deicher antigen in human colon cancer,
Cancer Res. 45 (1985) 3796e3802.
[18] Y.N. Malykh, R. Schauer, L. Shaw, N-Glycolylneuraminic acid in human tu-
mours, Biochimie 83 (2001) 623e634.
[19] J. Furukawa, M. Tsuda, K. Okada, T. Kimura, J. Piao, S. Tanaka, Y. Shinohara,
Comprehensive glycomics of a multistep human brain tumor model reveals
specific glycosylation patterns related to malignancy, PLoS One 10 (2015),
e0128300.
[20] G. Marquina, H. Waki, L.E. Fernandez, K. Kon, A. Carr, O. Valiente, R. Perez,
S. Ando, Gangliosides expressed in human breast cancer, Cancer Res. 56
(1996) 5165e5171.
[21] H. Higashi, T. Sasabe, Y. Fukui, M. Maru, S. Kato, Detection of gangliosides as
N-glycolylneuraminic acid-specific tumor-associated Hanganutziu-Deicher
antigen in human retinoblastoma cells, Jpn. J. Canc. Res. 79 (1988) 952e956.
[22] F. Priego-Capote, M.I. Orozco-Solano, M. Calderon-Santiago, M.D. Luque de
Castro, Quantitative determination and confirmatory analysis of N-ace-
tylneuraminic and N-glycolylneuraminic acids in serum and urine by solid-
phase extraction on-line coupled to liquid chromatography-tandem mass
spectrometry, J. Chromatogr. A 1346 (2014) 88e96.
[23] K. Kitajima, N. Varki, C. Sato, Advanced technologies in sialic acid and sialo-
glycoconjugate analysis, Top. Curr. Chem. 367 (2015) 75e103.
[24] S.L. Diaz, V. Padler-Karavani, D. Ghaderi, N. Hurtado-Ziola, H. Yu, X. Chen,
E.C. Brinkman-Van der Linden, A. Varki, N.M. Varki, Sensitive and specific
detection of the non-human sialic Acid N-glycolylneuraminic acid in human
tissues and biotherapeutic products, PLoS One 4 (2009) e4241.
[25] C.J. Day, A.W. Paton, M.A. Higgins, L.K. Shewell, F.E. Jen, B.L. Schulz,
B.P. Herdman, J.C. Paton, M.P. Jennings, Structure aided design of a Neu5Gc
specific lectin, Sci. Rep. 7 (2017) 1495.
[26] J. Wang, L.K. Shewell, A.W. Paton, J.C. Paton, C.J. Day, M.P. Jennings, Specificity
and utility of SubB2M, a new N-glycolylneuraminic acid lectin, Biochem.
Biophys. Res. Commun. 500 (2018) 765e771.
[27] A.W. Paton, P. Srimanote, U.M. Talbot, H. Wang, J.C. Paton, A new family of
potent AB(5) cytotoxins produced by Shiga toxigenic Escherichia coli, J. Exp.
Med. 200 (2004) 35e46.
[28] C.J. Day, V. Korolik, Identification of specific ligands for sensory receptors by
small-molecule ligand arrays and surface plasmon resonance, Methods Mol.
Biol. 1729 (2018) 303e317.
[29] T.L. Klug, R.C. Bast Jr., J.M. Niloff, R.C. Knapp, V.R. Zurawski Jr., Monoclonal
antibody immunoradiometric assay for an antigenic determinant (CA 125)
associated with human epithelial ovarian carcinomas, Cancer Res. 44 (1984)
1048e1053.
[30] R. Saldova, W.B. Struwe, K. Wynne, G. Elia, M.J. Duffy, P.M. Rudd, Exploring the
glycosylation of serum CA125, Int. J. Mol. Sci. 14 (2013) 15636e15654.
[31] R.G. Moore, A.K. Brown, M.C. Miller, S. Skates, W.J. Allard, T. Verch,
M. Steinhoff, G. Messerlian, P. DiSilvestro, C.O. Granai, R.C. Bast Jr., The use of
multiple novel tumor biomarkers for the detection of ovarian carcinoma in
patients with a pelvic mass, Gynecol. Oncol. 108 (2008) 402e408.
[32] A. Rump, Y. Morikawa, M. Tanaka, S. Minami, N. Umesaki, M. Takeuchi,
A. Miyajima, Binding of ovarian cancer antigen CA125/MUC16 to mesothelin
mediates cell adhesion, J. Biol. Chem. 279 (2004) 9190e9198.
[33] J.F. Masson, Surface plasmon resonance clinical biosensors for medical di-
agnostics, ACS Sens. 2 (2017) 16e30.
[34] P. Tangvoranuntakul, P. Gagneux, S. Diaz, M. Bardor, N. Varki, A. Varki,
L.K. Shewell et al. / Biochemical and Biophysical Research Communications 507 (2018) 173e177 177E. Muchmore, Human uptake and incorporation of an immunogenic
nonhuman dietary sialic acid, Proc. Natl. Acad. Sci. U. S. A. 100 (2003)
12045e12050.
[35] P.A. Bousquet, J.A. Sandvik, N.F. Jeppesen Edin, U. Krengel, Hypothesis:hypoxia induces de novo synthesis of NeuGc gangliosides in humans through
CMAH domain substitute, Biochem. Biophys. Res. Commun. 495 (2018)
1562e1566.
